NRP1 and prostate cancer: The expressions of ZEB1 and NRP-1 showed a decrease with siRNA-ZEB1- and siRNA-NRP-1-loaded cyclodextrin nanoparticles in PCa cells, suggesting the capability of these nanocarriers for the delivery of siRNAs and the effective treatment of prostate cancer via knocking down the level of expression to about 76.99% ± 10.89% [222].